Glioma

Symptoms

Glioma symptoms vary depending on the tumor’s size, location, and growth rate. Because different areas of the brain control different functions, symptoms may include headaches, seizures, weakness or numbness, difficulty speaking, changes in vision, problems with balance, or changes in memory, concentration, or personality.

Slower-growing gliomas may cause subtle symptoms that develop gradually over months or years, because the brain adapts as the tumor expands. More aggressive tumors cause symptoms that appear or worsen over weeks. In many patients, a seizure is the first sign that leads to brain imaging and diagnosis — and how quickly symptoms have developed is itself one of the first clues to what kind of glioma is present.

Tumor location also shapes the picture as much as the tumor type does. Tumors in the brainstem or around the fluid pathways can cause double vision, difficulty swallowing, or unsteadiness rather than seizures, and tumors that block the flow of spinal fluid can raise pressure inside the skull quickly.

Diagnosis

Imaging

Diagnosis typically begins with an MRI of the brain with and without contrast, defining the tumor’s location, size, and relationship to surrounding structures. Advanced sequences add more: perfusion imaging assesses the tumor’s blood supply, MR spectroscopy examines its chemical composition, and functional MRI with diffusion tensor tractography maps the language, motor, and visual pathways running near it. When a tumor involves the spine or the fluid pathways, imaging of the entire brain and spinal cord may be needed. Together these studies often suggest what type of glioma is present. What they cannot do is establish the diagnosis, because tumors of very different types can look alike on a scan.

Tissue & Molecular Testing

A definitive diagnosis requires tumor tissue obtained through surgical removal or biopsy. A neuropathologist examines the tissue and molecular testing determines the specific type of glioma. Which markers matter depends on the tumor. In the diffuse gliomas of adults, IDH mutation status is the first branch point and 1p/19q co-deletion the second. In midline tumors, H3 K27 alterations define the diagnosis. In circumscribed tumors such as pilocytic astrocytoma, BRAF alterations do. In ependymoma, the molecular group and the location together define the tumor. Next-generation sequencing finds alterations that older single-marker testing would miss, and DNA methylation profiling can classify tumors that remain unresolved.

The final pathology report is what pathologists call an integrated diagnosis: a layered result combining the microscopic appearance, the molecular findings, and a WHO grade drawn from both. National guidelines now place this molecular workup in the initial evaluation of any diffuse glioma rather than treating it as an optional addition.

Multidisciplinary Review

At Atlantic Brain and Spine, imaging, pathology, and molecular findings are reviewed as part of a multidisciplinary brain tumor evaluation before a treatment plan is finalized.

Treatment

Treatment for a glioma depends on the specific tumor type, grade, molecular characteristics, size, location, symptoms, and the patient’s overall health.

Surgery & Molecular Diagnosis

Surgery is usually the first treatment when a tumor can be safely removed. The goal is maximal safe resection — removing as much tumor as possible while protecting neurological function — and obtaining tissue adequate for full molecular testing. Across nearly every glioma type, more complete removal is associated with longer time to progression, which is why these operations are planned around what can be removed safely rather than around what is easiest to reach. For some tumors, surgery is not about removal at all: when a tumor sits in the brainstem or another location where resection is not possible, a small biopsy is performed to establish the molecular diagnosis that treatment will depend on.

At Atlantic Brain and Spine, tumors near critical territory are approached with a combination of techniques. Frameless stereotactic navigation merges the preoperative MRI, functional MRI, and tractography into a three-dimensional map used throughout the case. Awake craniotomy with direct cortical and subcortical stimulation allows language and motor pathways to be identified and tested in real time while the tumor is removed. Continuous intraoperative neurophysiologic monitoring tracks those pathways under general anesthesia. For high-grade tumors, fluorescence-guided resection makes tumor tissue visibly distinct from surrounding brain, helping find margins the eye alone would miss.

Treatment After Surgery

What follows surgery depends entirely on the specific diagnosis, and the differences are large. A pilocytic astrocytoma that has been completely removed may need no further treatment at all, only periodic imaging. A grade 2 oligodendroglioma completely removed may be watched for years. A glioblastoma is treated with radiation and chemotherapy beginning within weeks of surgery. A diffuse midline glioma is treated primarily with radiation, and now also with a targeted oral medication approved specifically for tumors carrying the H3 K27M alteration. Some gliomas are also treated with radiation delivered directly into the surgical cavity, with a wearable device that interferes with tumor cell division, or through a clinical trial matched to the tumor’s molecular profile.